Captrust Financial Advisors Fibrogen Inc Transaction History

Captrust Financial Advisors

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.38 - $0.91 $393 - $941	-1,035 Reduced 6.28%	15,450 $13,000
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $13,023 - $46,652	16,485 New	16,485 $14,000
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $162,753 - $256,936	10,204 New	10,204 $190,000
Q2 2022 Aug 16, 2022	BUY	$7.94 - $12.96 $12,489 - $20,386	1,573 Added 368.38%	2,000 $21,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $11,070 - $15,463	-921 Reduced 68.32%	427 $5,000
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $347 - $538	35 Added 2.67%	1,348 $19,000
Q3 2021 Nov 16, 2021	BUY	$10.18 - $26.64 $4,855 - $12,707	477 Added 57.06%	1,313 $13,000
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $6,425 - $12,345	-346 Reduced 29.27%	836 $22,000
Q1 2021 May 17, 2021	BUY	$31.0 - $55.72 $5,642 - $10,141	182 Added 18.2%	1,182 $41,000
Q3 2020 Nov 17, 2020	BUY	$40.47 - $45.5 $32,376 - $36,400	800 Added 400.0%	1,000 $41,000
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $6,514 - $8,566	200 New	200 $8,000
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $69,160 - $96,120	-2,000 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$35.13 - $55.53 $70,260 - $111,060	2,000 New	2,000 $90,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.